| Application no. and date | 01903262.2 (espacenet) (Federated) (European Patent Register), 20010124 | | Patent/reg. no. and date | DK/EP 1250146, 20040102 | | Publication date | 20021023 | | Priority no. and date | US 491420, 20000126 | | EP pub. no. and date |
EP 1250146 20021023 | | Effective date | | | Applicant/owner | Allergan, Inc., 2525 Dupont Drive,
Irvine, CA 92612, US | | Applicant ref. no. | 117169 | | Inventor | DONOVAN, Stephen, 27252 Calle Anejo
Capistrano Beach, CA 92624, US | | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K | | Opponent | | | IPC Class | A61K 38/16 (2006.01) , A61P 5/48 (2006.01) | | Title | Anvendelse af botulinumtoxin til behandling af diabetes | | Int. application no. | US2001002273 | | Int. publication no. | WO2001054711 | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
